RADIKAL THERAPEUTICS, INC.

Basic Information

8 SOLVIVA RD
WEST TISBURY, MA, 02575-1626

Company Profile

n/a

Additional Details

Field Value
DUNS: 833130045
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: Y
Number of Employees: n/a


  1. A Novel Immunotolerizing Therapy for Autoimmune Vitiligo

    Amount: $225,000.00

    DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is pioneering a novel therapy to restore immune tolerance and arrest progressive depigmentation in vitiligo. At Loyola University (LUC), ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. A novel prodrug for K+-ATP channel activation in the glaucomatous eye

    Amount: $225,919.00

    DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is developing a revolutionary bifunctional small molecule (R-801) for topical therapy of primary open angle glaucoma (POAG). R-801 is co ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. Bifunctional potassium-ATP channel opener and redox catalyst for therapy of spina

    Amount: $231,477.00

    DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is developing a first-in-class cytoprotective small molecule (R-801) for the prevention of spinal cord injury (SCI) based upon the chem ...

    SBIR Phase I 2014 Department of Health and Human Services
  4. A potassium-ATP channel opener for prevention of contrast-induced nephropathy

    Amount: $1,527,261.00

    Contrast media (CM) induced nephropathy (CIN) remains prevalent and debilitating, the third most common cause of acute renal failure. Based on more than 80 million (M) CM injections in the USA per ann ...

    SBIR Phase II 2014 Department of Health and Human Services
  5. A Novel Therapy for Restricted Induction of Tolerance to Treat Diabetes Mellitus

    Amount: $269,865.00

    DESCRIPTION (provided by applicant): We are developing a novel immunomodulatory approach to arrest pancreatic islet injury and restore specific immune tolerance in new-onset Type 1 diabetes mellitus ( ...

    SBIR Phase I 2013 Department of Health and Human Services
  6. Radiocontrast Nephropathy: Redox Degradation Catalyst and Nitric Oxide Donor

    Amount: $245,133.00

    DESCRIPTION (provided by applicant): We are developing a novel small molecule cytoprotective drug (R-100) for the prevention of contrast- induced nephropathy (CIN) following IV radiocontrast media (CM ...

    SBIR Phase I 2013 Department of Health and Human Services
  7. A Bifunctional Katp Channel Activator and Redox Mimetic for BPD

    Amount: $266,919.00

    DESCRIPTION (provided by applicant): Radikal Therapeutics is developing a novel small molecule therapy (R-801) for neonatal prematurity that triggers an endogenous cytoprotective defense and thereby ...

    SBIR Phase I 2013 Department of Health and Human Services
  8. Hybrid Katp Channel Opener and Redox Catalyst for Lung Transplantation

    Amount: $296,339.00

    DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is developing a novel cytoprotective agent (R-801) for the prevention of ischemia-reperfusion injury (IRI) following lung transplantati ...

    SBIR Phase I 2013 Department of Health and Human Services
  9. A Wearable Balance Booster- Stepping Closer to the Market

    Amount: $308,160.00

    DESCRIPTION (provided by applicant): High volume mechanical ventilation (MV) induces a lethal pulmonary complication, termed ventilator induced lung injury (VILI), via the generation of toxic free ...

    SBIR Phase I 2013 Department of Health and Human Services
  10. DFG-out inhibitors of Abl-kinases to treat PML

    Amount: $378,009.00

    DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is developing a novel pharmaceutical therapy for prematurity that targets a developmental deficiency in thioredoxin (Trx), a protein tha ...

    SBIR Phase I 2013 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government